2022
DOI: 10.3332/ecancer.2022.1344
|View full text |Cite
|
Sign up to set email alerts
|

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door

Abstract: Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially improve treatment safety for a large number of patients, saving lives, avoiding complications and reducing health care costs. This article discusses how personalisation of fluoropyrimidine treatment based on the identification of DP… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…Current evidence suggests that the combination of these variations is a significant contributor to the development of adverse events, responsible for at least 20% of the documented instances of severe toxicities associated with 5-FU. 26…”
Section: Dpd Deficientmentioning
confidence: 99%
“…Current evidence suggests that the combination of these variations is a significant contributor to the development of adverse events, responsible for at least 20% of the documented instances of severe toxicities associated with 5-FU. 26…”
Section: Dpd Deficientmentioning
confidence: 99%